See also separate entry for meropenem.
- Trade Name: Vabomere (Rempex)
- Indications: Complicated urinary tract infections caused by susceptible bacteria
- Class: Antibiotic, Antibiotic; carbapenem (meropenem), Antimicrobial, Beta-lactamase inhibitor (vaborbactam)
- Half-life: 1–2 hours
- FDA Approval Date: 08/29/2017
- Clinically important, potentially hazardous interactions with:
Probenecid, Valproic Acid - Pregnancy: Potential risk to fetus based on animal studies
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
